Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Plos Genetics|January 25, 2018
Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways and functionsZuchra Zakirova, Tomas Fanutza, Justine Bonet, et al.
Nature Communications|August 25, 2019
Integrative transcriptome imputation reveals tissue-specific and shared biological mechanisms mediating susceptibility to complex traitsWen Zhang, Georgios Voloudakis, Veera M Rajagopal, et al.
Circulation. Genomic and Precision Medicine|May 7, 2019
Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral TherapyItziar Frades, Ben Readhead, Letizia Amadori, et al.
Briefings in Bioinformatics|February 16, 2017
Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioningKhader Shameer, Benjamin S Glicksberg, Rachel Hodos, et al.
Nature Neuroscience|August 1, 2017
Necroptosis activation in Alzheimer's diseaseAntonella Caccamo, Caterina Branca, Ignazio S Piras, et al.
Molecular Psychiatry|October 5, 2018
Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in cerebral Aβ amyloidosis mouse normalizes clinical phenotype and complement subnetwork molecular pathology without reducing Aβ burdenJean-Vianney Haure-Mirande, Minghui Wang, Mickael Audrain, et al.
Molecular Psychiatry|November 23, 2018
Correction: Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in cerebral Aβ amyloidosis mouse normalizes clinical phenotype and complement subnetwork molecular pathology without reducing Aβ burdenJean-Vianney Haure-Mirande, Minghui Wang, Mickael Audrain, et al.
Acta Neuropathologica|June 15, 2017
Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathologyJean-Vianney Haure-Mirande, Mickael Audrain, Tomas Fanutza, et al.
Molecular Cancer Therapeutics|June 18, 2020
A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) InhibitionEkaterina A Lesovaya, Alena V Savinkova, Olga V Morozova, et al.
The Lancet. Psychiatry|February 27, 2016
Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approachDouglas M Ruderfer, Alexander W Charney, Ben Readhead, et al.
Pageof 5